Gemcitabine‐associated thrombotic microangiopathy
Benjamin D. Humphreys(Washington University in St. Louis), Colm Magee(Massachusetts General Hospital), Helmut G. Rennke(Brigham and Women's Hospital), Andrew X. Zhu(University of California San Diego), Peter Marks(Center for Biologics Evaluation and Research), Jeffrey W. Clark(Massachusetts General Hospital), Joel Henderson, Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center)
Cited by 179
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k